Waldencast (WALD) Aandelenoverzicht
Waldencast plc is actief in de schoonheids- en wellnessbranche in de Verenigde Staten, Canada, Europa, het Midden-Oosten, India, Australië en Nieuw-Zeeland. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 4/6 |
| Dividenden | 0/6 |
WALD Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Waldencast plc Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$1.73 |
| 52 Week Hoogtepunt | US$3.22 |
| 52 Week Laag | US$0.72 |
| Bèta | -0.042 |
| 1 maand verandering | -6.99% |
| 3 maanden verandering | 64.76% |
| 1 Jaar Verandering | -31.89% |
| 3 jaar verandering | -74.37% |
| 5 jaar verandering | n/a |
| Verandering sinds IPO | -77.56% |
Recent nieuws en updates
Narratiefupdate • Jun 29
WALD: Obagi Sale And Injectables Expansion Will Support Future Share Rebound
The analyst price target for Waldencast has been raised from $1.87 to $2.28, with analysts pointing to the announced sale of the Obagi skin care and aesthetics business for up to $460 million as a key factor supporting the higher valuation. What’s in the News for Waldencast Waldencast announced that the U.S. Food and Drug Administration approved Obagi saypha ChIQ injectable hyaluronic acid gel, expanding the Obagi Medical injectable portfolio and targeting cheek augmentation and midface contour correction for patients over 21.
Narratiefupdate • Jun 15
WALD: Obagi Sale And Injectables Launch Will Support Future Upside
Analysts have lifted their price target on Waldencast stock to $3.00 from $2.50, citing the agreed sale of the Obagi skin care and aesthetics business for up to $460m and the view that current valuation does not fully reflect the strength of Obagi, Milk and the upcoming Saypha injectables launch. Analyst Commentary Bullish analysts see the agreed sale of the Obagi skin care and aesthetics business and the ongoing investment in Saypha injectables as key supports for the recent reset to a $3.00 price target.
Narratiefupdate • Jun 01
WALD: Brand Strength And Injectables Expansion Will Drive Future Repricing Despite Higher Costs
Narrative Update on Waldencast Analysts have lowered their average price targets on Waldencast by about $1 to a range around $2 to $2.50, citing recent EBITDA and sales misses, ongoing costs tied to regulatory and review processes, and what they describe as slower recent growth. At the same time, they continue to point to the perceived strength of the Obagi and Milk brands, as well as potential from the Saypha injectables launch.Recent updates
Narratiefupdate • Jun 29
WALD: Obagi Sale And Injectables Expansion Will Support Future Share Rebound
The analyst price target for Waldencast has been raised from $1.87 to $2.28, with analysts pointing to the announced sale of the Obagi skin care and aesthetics business for up to $460 million as a key factor supporting the higher valuation. What’s in the News for Waldencast Waldencast announced that the U.S. Food and Drug Administration approved Obagi saypha ChIQ injectable hyaluronic acid gel, expanding the Obagi Medical injectable portfolio and targeting cheek augmentation and midface contour correction for patients over 21.Narratiefupdate • Jun 15
WALD: Obagi Sale And Injectables Launch Will Support Future Upside
Analysts have lifted their price target on Waldencast stock to $3.00 from $2.50, citing the agreed sale of the Obagi skin care and aesthetics business for up to $460m and the view that current valuation does not fully reflect the strength of Obagi, Milk and the upcoming Saypha injectables launch. Analyst Commentary Bullish analysts see the agreed sale of the Obagi skin care and aesthetics business and the ongoing investment in Saypha injectables as key supports for the recent reset to a $3.00 price target.Narratiefupdate • Jun 01
WALD: Brand Strength And Injectables Expansion Will Drive Future Repricing Despite Higher Costs
Narrative Update on Waldencast Analysts have lowered their average price targets on Waldencast by about $1 to a range around $2 to $2.50, citing recent EBITDA and sales misses, ongoing costs tied to regulatory and review processes, and what they describe as slower recent growth. At the same time, they continue to point to the perceived strength of the Obagi and Milk brands, as well as potential from the Saypha injectables launch.Narratiefupdate • May 04
WALD: Brand Strength And Injectables Launch Will Support Future Share Rebound
Analysts have trimmed their average price target on Waldencast from about $3.08 to roughly $1.87, reflecting recent EBITDA and sales shortfalls, slower growth and higher costs. At the same time, they point to ongoing brand strength and potential upside from the Saypha injectables launch.Narratiefupdate • Apr 20
WALD: Brand Strength And Injectables Rollout Will Support Future Repricing
Analysts have trimmed their average price target for Waldencast to a range of $2.00 to $2.50, reflecting recent EBITDA and sales shortfalls, higher ongoing review and investigation costs, and more moderate revenue growth assumptions. They continue to highlight the strength of the Obagi and Milk brands, as well as potential upside from the Saypha injectables launch.Narratiefupdate • Apr 05
WALD: Brand Equity And Aesthetics Partnerships Will Support Future Upside
Analysts have trimmed their average price targets for Waldencast to a range of about $2 to $2.50 from prior levels near $3 to $4, citing recent EBITDA and sales misses, ongoing SEC and review related costs, and the view that the brands still have room to grow despite a transition period. Analyst Commentary Recent research updates show that while targets have been reduced, several bullish analysts still view Waldencast as an early stage, brand driven story in a transition phase.Narratiefupdate • Mar 22
WALD: Aesthetics Partnerships And Brand Strength Will Support Future Upside
Analysts have trimmed their average price target on Waldencast to $2.50, down from $4.00, reflecting recent earnings misses, ongoing investment in the Saypha injectables launch, slower-than-expected growth and higher costs tied to regulatory and review processes, even as they continue to highlight the strength of the Obagi and Milk brands. Analyst Commentary Bullish analysts are cutting their price targets on Waldencast, but several still point to what they see as underappreciated assets and future product catalysts.Narratiefupdate • Mar 07
WALD: Jefferies Buy Rating And Aesthetics Partnerships Will Support $4 Upside
Analysts have raised their blended price target for Waldencast to $4.00, citing updated assumptions that include a lower discount rate, an adjusted profit margin outlook, and a higher future P/E multiple, as well as support from recent Street research. Analyst Commentary Street research around Waldencast has tilted constructive, with bullish analysts pointing to a clearer earnings path and a more supportive valuation framework behind the updated US$4.00 blended price target.Narratiefupdate • Feb 21
WALD: Future Margin Recovery And Distribution Gains Will Support Share Rebound
Analysts have held Waldencast's price target at $3.00, with the latest updates reflecting lower assumed profit margins and a higher future P/E multiple, while incorporating mixed recent research that includes a Buy initiation and a prior downgrade after "disappointing" Q2 results and a reduced FY25 outlook. Analyst Commentary Recent commentary around Waldencast reflects a split view, with some focusing on long term brand potential and others zeroing in on execution hiccups and trimmed outlooks.Narratiefupdate • Feb 06
WALD: Future Retail Distribution Gains Will Support Recovery After Earnings Setbacks
Narrative Update on Waldencast The analyst price target for Waldencast has been revised slightly lower to about $3.08 from about $3.20, as analysts balance a higher discount rate and a lower assumed future P/E with generally supportive views following the recent Jefferies initiation, along with concerns highlighted after Telsey's reaction to "disappointing" Q2 results and the reduced FY25 outlook. Analyst Commentary Recent research on Waldencast reflects a mix of optimism around the long term brand opportunity and caution around execution and near term earnings delivery.Narratiefupdate • Jan 23
WALD: Expanded Beauty Distribution Will Support $4 Upside After Mixed Research
Analysts have trimmed their price target on Waldencast to $4.00, reflecting a slightly higher discount rate and modest adjustments to growth and P/E assumptions following mixed recent research, including a downgrade after "disappointing" Q2 results and an assumed rating elsewhere. Analyst Commentary Recent research on Waldencast sends a mixed signal, with one firm trimming its stance after Q2 and another assuming coverage with a more constructive view.Analyseartikel • Jan 10
Waldencast plc's (NASDAQ:WALD) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors
Waldencast plc ( NASDAQ:WALD ) shareholders won't be pleased to see that the share price has had a very rough month...Narratiefupdate • Jan 07
WALD: Expanded Beauty Distribution Will Support Recovery After Recent Guidance Reset
Analysts now hold Waldencast's fair value steady at about US$4.00 per share, with a US$3.00 price target that reflects caution after what they describe as disappointing Q2 results, reduced FY25 guidance, and sales pressure at the Milk brand despite broader distribution gains. Analyst Commentary Even with the recent downgrade and cautious stance on near term execution, some commentary still points to potential upside drivers that investors are watching closely.Narratiefupdate • Dec 14
WALD: Expanded Beauty Distribution Will Drive Rebound After Recent Earnings Reset
Analysts have trimmed their price target on Waldencast to about $4 from roughly $5, citing weaker than expected Q2 results, a lowered FY25 outlook, and slower growth at key brand Milk despite new distribution gains. Analyst Commentary Bullish analysts acknowledge that recent results and guidance have pressured near term expectations, but they continue to see upside potential for Waldencast as execution improves and the growth algorithm normalizes.Narratiefupdate • Nov 28
WALD: Future Retail Partnerships Will Drive Recovery After Recent Setbacks
Analysts have revised Waldencast's price target downward from $3.50 to $3.20, citing weaker than expected quarterly results and ongoing challenges impacting sales growth and profitability. Analyst Commentary Bullish Takeaways Despite near-term headwinds, Waldencast continues to increase its distribution footprint.Analyseartikel • Nov 26
Waldencast (NASDAQ:WALD) Is Carrying A Fair Bit Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • Nov 26
Revenues Tell The Story For Waldencast plc (NASDAQ:WALD) As Its Stock Soars 33%
Waldencast plc ( NASDAQ:WALD ) shares have continued their recent momentum with a 33% gain in the last month alone. Not...Seeking Alpha • Sep 23
Waldencast: Fairly Valued With Ulta Lift Already Reflected, Saypha Deal Adds Optionality
Summary Waldencast faces ongoing challenges with slowing revenue growth, heavy debt, and profitability concerns despite recent margin expansion. WALD's acquisition of Novaestiq aims to double its addressable market by entering the U.S. dermal filler space under the Obagi brand, with risk-mitigating deal terms. Recent trading updates show Milk Makeup's U.S. growth via Ulta and Amazon, while Obagi excels internationally, but overall FY 2025 guidance has been lowered. Despite a potential 20% upside to the $2.50–2.70 range, I maintain a 'Hold' rating as structural issues and dilution risks persist. Read the full article on Seeking AlphaAnalyseartikel • Aug 21
Waldencast plc (NASDAQ:WALD) Stocks Pounded By 26% But Not Lagging Industry On Growth Or Pricing
NasdaqCM:WALD 1 Year Share Price vs Fair Value Explore Waldencast's Fair Values from the Community and select yours The...Narratiefupdate • Aug 21
Expansion Into Ulta Beauty Stores Will Boost Future Success
The Analyst Price Target for Waldencast was reduced to $3.50 from $3.98, reflecting concerns about softer international demand, operational disruptions, strategic uncertainty, and delayed reporting, despite some positive momentum at core brands. Analyst Commentary Moderated annual outlook due to softening international consumption and out-of-stock issues at Waldencast brands.Analyseartikel • May 14
We Think Waldencast (NASDAQ:WALD) Has A Fair Chunk Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analyseartikel • Apr 09
It's Down 29% But Waldencast plc (NASDAQ:WALD) Could Be Riskier Than It Looks
Waldencast plc ( NASDAQ:WALD ) shareholders that were waiting for something to happen have been dealt a blow with a 29...
Nieuw narratief • Mar 30
Expansion Into Ulta Beauty Stores Will Boost Future Success
Strong growth in Milk Makeup and Obagi Medical, with store expansion and innovation driving increased future revenue and market share.Analyseartikel • Aug 13
Waldencast plc (NASDAQ:WALD) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
To the annoyance of some shareholders, Waldencast plc ( NASDAQ:WALD ) shares are down a considerable 26% in the last...Seeking Alpha • Jun 28
Waldencast Plc: Investors Continue To Demand More Growth
Summary Waldencast plc provides 'Milk Makeup' & 'Obagi' brands in beauty & wellness industry. Q1 2024 saw 21% revenue growth, improved profitability trends, and increased adjusted EBITDA for Waldencast. Fiscal 2024 guidance includes expectations of continued growth through e-commerce, international sales, and brand partnerships. Read the full article on Seeking AlphaAnalyseartikel • Jun 19
We Think Waldencast (NASDAQ:WALD) Has A Fair Chunk Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • May 11
Waldencast plc (NASDAQ:WALD) Shares Slammed 29% But Getting In Cheap Might Be Difficult Regardless
To the annoyance of some shareholders, Waldencast plc ( NASDAQ:WALD ) shares are down a considerable 29% in the last...Analyseartikel • Apr 07
Waldencast plc's (NASDAQ:WALD) Intrinsic Value Is Potentially 55% Above Its Share Price
Key Insights Waldencast's estimated fair value is US$14.29 based on 2 Stage Free Cash Flow to Equity Waldencast's...Analyseartikel • Dec 14
Is Waldencast plc (NASDAQ:WALD) Trading At A 42% Discount?
How far off is Waldencast plc ( NASDAQ:WALD ) from its intrinsic value? Using the most recent financial data, we'll...Rendement voor aandeelhouders
| WALD | US Personal Products | US Markt | |
|---|---|---|---|
| 7D | 3.0% | -1.5% | 0.8% |
| 1Y | -31.9% | -16.5% | 20.6% |
Rendement versus industrie: WALD presteerde slechter dan de US Personal Products -sector, die het afgelopen jaar een rendement van -16.5 % opleverde.
Rendement versus markt: WALD presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 20.6 % opleverde.
Prijsvolatiliteit
| WALD volatility | |
|---|---|
| WALD Average Weekly Movement | 22.1% |
| Personal Products Industry Average Movement | 8.0% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiele aandelenkoers: De aandelenkoers van WALD is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van WALD is het afgelopen jaar gestegen van 15% naar 22%.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2020 | 367 | Michel Brousset | www.waldencast.com |
Waldencast plc is actief in de schoonheids- en welzijnsindustrie in de Verenigde Staten, Canada, Europa, het Midden-Oosten, India, Australië en Nieuw-Zeeland. Het bedrijf is actief via twee segmenten, Obagi Medical en Milk Makeup. Het biedt huidverzorgingsproducten om tekenen van huidveroudering te minimaliseren, donkere vlekken, hyperpigmentatie, fijne lijntjes en rimpels aan te pakken, en de huidtint en textuur te beschermen en te verbeteren; cosmetica; en andere schoonheidsproducten.
Waldencast plc Samenvatting
| WALD fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$221.89m |
| Inkomsten(TTM) | -US$229.75m |
| Inkomsten(TTM) | US$272.07m |
0.8x
P/S-verhouding-0.9x
Koers/WinstverhoudingIs WALD overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| WALD resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$272.07m |
| Kosten van inkomsten | US$89.05m |
| Brutowinst | US$183.02m |
| Overige uitgaven | US$412.77m |
| Inkomsten | -US$229.75m |
Laatst gerapporteerde inkomsten
Dec 31, 2025
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -1.94 |
| Brutomarge | 67.27% |
| Nettowinstmarge | -84.44% |
| Schuld/Eigen Vermogen Verhouding | 27.3% |
Hoe presteerde WALD op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/12 10:10 |
| Aandelenkoers aan het einde van de dag | 2026/07/10 00:00 |
| Inkomsten | 2025/12/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Waldencast plc wordt gevolgd door 4 analisten. 3 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Susan Anderson | Canaccord Genuity |
| Jungwon Kim | TD Cowen |